Annette Hogg

Early therapeutic response assessment by 18FDG-positron emission tomography during chemotherapy in patients with diffuse large B-cell lymphoma: Isolated residual positivity involving bone is not usually a predictor of subsequent treatment failure (2007)

Ng, Dr. Ashley P., Wirth, Dr. Andrew, Seymour, Dr. John, Lee, Dr. Michael, Hogg, Dr. Annette, Januszewicz, Dr. Henry, ...

Residual 2-fluoro-2-deoxyglucose (FDG) – positron emission tomography (PET) positivity during treatment of patients with diffuse large B-cell lymphoma (DLBLC) prospectively identifies a subgroup at...

Early therapeutic response assessment by 18FDG-positron emission tomography during chemotherapy in patients with diffuse large B-cell lymphoma: Isolated residual positivity involving bone is not usually a predictor of subsequent treatment failure (2007)

Ng, Dr. Ashley P., Wirth, Dr. Andrew, Seymour, Dr. John, Lee, Dr. Michael, Hogg, Dr. Annette, Januszewicz, Dr. Henry, ...

Residual 2-fluoro-2-deoxyglucose (FDG) – positron emission tomography (PET) positivity during treatment of patients with diffuse large B-cell lymphoma (DLBLC) prospectively identifies a subgroup at...

Early therapeutic response assessment by 18FDG-positron emission tomography during chemotherapy in patients with diffuse large B-cell lymphoma: Isolated residual positivity involving bone is not usually a predictor of subsequent treatment failure (2007)

Ng, Dr. Ashley P., Wirth, Dr. Andrew, Seymour, Dr. John, Lee, Dr. Michael, Hogg, Dr. Annette, Januszewicz, Dr. Henry, ...

Residual 2-fluoro-2-deoxyglucose (FDG) – positron emission tomography (PET) positivity during treatment of patients with diffuse large B-cell lymphoma (DLBLC) prospectively identifies a...

Early therapeutic response assessment by 18FDG-positron emissiontomography during chemotherapy in patients with diffuse large B-celllymphoma: Isolated residual positivity involving bone is not usually apredictor of subsequent treatment failure (2007)

Ng, Dr. Ashley P., Wirth, Dr. Andrew, Seymour, Dr. John, Lee, Dr. Michael, Hogg, Dr. Annette, Januszewicz, Dr. Henry, ...

Residual 2-fluoro-2-deoxyglucose (FDG) – positron emission tomography (PET) positivity during treatment of patients withdiffuse large B-cell lymphoma (DLBLC) prospectively identifies a subgroup at...

Early therapeutic response assessment by 18FDG-positron emissiontomography during chemotherapy in patients with diffuse large B-celllymphoma: Isolated residual positivity involving bone is not usually apredictor of subsequent treatment failure (2007)

Ng, Dr. Ashley P., Wirth, Dr. Andrew, Seymour, Dr. John, Lee, Dr. Michael, Hogg, Dr. Annette, Januszewicz, Dr. Henry, ...

Residual 2-fluoro-2-deoxyglucose (FDG) – positron emission tomography (PET) positivity during treatment of patients withdiffuse large B-cell lymphoma (DLBLC) prospectively identifies a subgroup at...

Early therapeutic response assessment by 18FDG-positron emissiontomography during chemotherapy in patients with diffuse large B-celllymphoma: Isolated residual positivity involving bone is not usually apredictor of subsequent treatment failure (2007)

Ng, Dr. Ashley P., Wirth, Dr. Andrew, Seymour, Dr. John, Lee, Dr. Michael, Hogg, Dr. Annette, Januszewicz, Dr. Henry, ...

Residual 2-fluoro-2-deoxyglucose (FDG) – positron emission tomography (PET) positivity during treatment of patients withdiffuse large B-cell lymphoma (DLBLC) prospectively identifies a subgroup at...

Early therapeutic response assessment by 18FDG-positron emissiontomography during chemotherapy in patients with diffuse large B-celllymphoma: Isolated residual positivity involving bone is not usually apredictor of subsequent treatment failure (2007)

Ng, Dr. Ashley P., Wirth, Dr. Andrew, Seymour, Dr. John, Lee, Dr. Michael, Hogg, Dr. Annette, Januszewicz, Dr. Henry, ...

Residual 2-fluoro-2-deoxyglucose (FDG) – positron emission tomography (PET) positivity during treatment of patients withdiffuse large B-cell lymphoma (DLBLC) prospectively identifies a subgroup at...

Early therapeutic response assessment by 18FDG-positron emissiontomography during chemotherapy in patients with diffuse large B-celllymphoma: Isolated residual positivity involving bone is not usually apredictor of subsequent treatment failure

Ng, Dr. Ashley P., Wirth, Dr. Andrew, Seymour, Dr. John, Lee, Dr. Michael, Hogg, Dr. Annette, Januszewicz, Dr. Henry, ...

Residual 2-fluoro-2-deoxyglucose (FDG) – positron emission tomography (PET) positivity during treatment of patients withdiffuse large B-cell lymphoma (DLBLC) prospectively identifies a subgroup at...